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Smooth-muscle BMAL1 participates in blood pressure
circadian rhythm regulation
Zhongwen Xie,1,2 Wen Su,3 Shu Liu,3 Guogang Zhao,3 Karyn Esser,1 Elizabeth A. Schroder,1 Mellani Lefta,1 Harald M. Stauss,4
Zhenheng Guo,3 and Ming Cui Gong1
Department of Physiology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA. 2Key Laboratory of Tea Biochemistry and Biotechnology, Ministry of Agriculture and Ministry of Educa-

1

tion, Anhui Agricultural University, Anhui, China. 3Department of Internal Medicine, College of Medicine, University of Kentucky, Lexington, Kentucky, USA. 4Department of Health and Human Physiology,
The University of Iowa, Iowa City, Iowa, USA.

As the central pacemaker, the suprachiasmatic nucleus (SCN) has long been considered the primary regulator of blood
pressure circadian rhythm; however, this dogma has been challenged by the discovery that each of the clock genes present
in the SCN is also expressed and functions in peripheral tissues. The involvement and contribution of these peripheral
clock genes in the circadian rhythm of blood pressure remains uncertain. Here, we demonstrate that selective deletion
of the circadian clock transcriptional activator aryl hydrocarbon receptor nuclear translocator–like (Bmal1) from smooth
muscle, but not from cardiomyocytes, compromised blood pressure circadian rhythm and decreased blood pressure without
affecting SCN-controlled locomotor activity in murine models. In mesenteric arteries, BMAL1 bound to the promoter of and
activated the transcription of Rho-kinase 2 (Rock2), and Bmal1 deletion abolished the time-of-day variations in response
to agonist-induced vasoconstriction, myosin phosphorylation, and ROCK2 activation. Together, these data indicate that
peripheral inputs contribute to the daily control of vasoconstriction and blood pressure and suggest that clock gene
expression outside of the SCN should be further evaluated to elucidate pathogenic mechanisms of diseases involving blood
pressure circadian rhythm disruption.

Introduction

Human blood pressure undergoes daily oscillations: blood pressure is lowest at night (nocturnal dip) and rises before awakening (morning surge) (1). Such blood pressure circadian rhythm is
critical to human health, as a 40% higher risk of acute myocardial
infarction, a 29% higher risk of sudden cardiac death, and a 49%
higher risk of stroke occur during the early morning blood pressure
surge compared with the rest of the day (2, 3). It was long believed
that blood pressure circadian rhythm, just like other physiological
and behavioral circadian rhythms, was mostly controlled by the
suprachiasmatic nucleus (SCN). However, this dogma was challenged by the discoveries that each of the core clock genes that
exists in the SCN also expresses and functions in peripheral tissues (4–7). These discoveries raise some fundamental questions:
do these peripheral clock genes participate in the regulation of
blood pressure circadian rhythm? And if so, which specific clock
genes in which peripheral tissue or tissues are important for blood
pressure circadian rhythm?
Smooth muscle is a major component of the blood vessel wall,
and its primary physiological function is to maintain adequate
organ blood supply and blood pressure homeostasis by adjusting
its contractile state in response to environmental cues (8). Smoothmuscle contractility exhibits time-of-day variation (9–14). However, whether and how such time-of-day smooth-muscle contractile
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variation relates to blood pressure circadian rhythm are unknown.
Moreover, the molecular mechanism that underlies time-of-day
smooth-muscle contractile variation is unknown.
Aryl hydrocarbon receptor nuclear translocator–like (BMAL1),
also known as Arntl3 in mouse and MOP3 in humans, is a central
element of the core clock genes in mammals. Global Bmal1 deletion in mice causes immediate and complete loss of rhythmicity,
including in blood pressure circadian rhythm (15, 16). BMAL1 is
expressed ubiquitously but functions in a tissue-specific manner. For instance, it has been shown that brain-specific BMAL1
expression in global Bmal1-knockout mice selectively restored
wheel-running circadian rhythm, and skeletal muscle–specific
BMAL1 expression selectively restored wheel-running level and
body weight (17). However, the physiological function of BMAL1
in smooth muscle and its contribution to blood pressure circadian rhythm remain to be defined. The current study developed
a smooth-muscle-specific Bmal1-knockout mouse model and
demonstrated in vitro and in vivo that smooth-muscle BMAL1 is
essential for normal vascular smooth-muscle contraction amplitude and time-of-day variations as well as blood pressure level
and circadian rhythm.

Results

Generation and characterization of a smooth-muscle–specific Bmal1knockout mouse model. We generated a smooth-muscle–specific
Bmal1-knockout mouse model (SM-Bmal1–KO) by crossing
Bmal1flox/flox mice (18) with smooth-muscle–specific SM22α-Cre
mice (19). SM-Bmal1–KO mice were viable, fertile, and grossly
normal. Four distinct approaches were taken to characterize
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SM-Bmal1–KO mice. First, SM-Bmal1–KO mice exhibited a Cremediated chromosome recombination that specifically deletes
the Bmal1 gene in smooth-muscle–enriched tissues, such as the
aorta, mesenteric artery, and bladder (Figure 1A). Second, Bmal1
mRNA (Figure 1B) and protein (Figure 1C) were drastically
decreased in mesenteric arteries from the SM-Bmal1–KO mice
compared with those in WT littermates (Bmal1flox/flox mice). Third,
the 24-hour mRNA oscillations of period circadian clock 1 (Per1)
and period circadian clock 2 (Per2), 2 BMAL1 target genes, were
abolished in mesenteric arteries by Bmal1 deletion (Figure 1, D
and E). In addition, in agreement with the literature (19, 20), we
also found that Cre recombinase was indeed expressed in heart
but at a much lower level than in smooth muscle (Z. Guo and M.
Gong, unpublished observations). In contrast to the drastic effect
of Bmal1 deletion in the mesenteric artery, Bmal1 deletion in the
heart had no effect on Per1 and Per2 mRNA 24-hour oscillation
(Figure 1, F and G). Finally, PER2 oscillation was monitored in real
time by measuring luminescence in mesenteric arteries or SCNcontaining brain slices isolated from SM-Bmal1–KO/mPer2Luc
knockin mice. PER2 oscillations were completely lost in mesenteric arteries (Figure 1H), but remained normal in SCN-containing brain slices (Figure 1I).
In addition, we measured the body weight, body fat mass,
fasting blood glucose, glucose tolerance, and insulin tolerance
in SM-Bmal1–KO mice and WT littermates to determine whether
the disruptions of adipogenesis and glucose metabolism reported
in global Bmal1-KO mice (21) are present in the SM-Bmal1–KO
mice. No difference was detected in any of these indices (Z. Guo
and M. Gong, unpublished observations). We also measured
kidney weight and length to determine whether the reduction
of kidney mass in the absence of degenerative lesions reported
in global Bmal1-KO mice (22) occurs in SM-Bmal1–KO mice. No
difference was found between SM-Bmal1–KO mice and WT littermates (Z. Guo and M. Gong, unpublished observations). Consistent with those findings, we also did not find any significant difference in urine volume and blood sodium concentration between
SM-Bmal1–KO mice and WT littermates (Z. Guo and M. Gong,
unpublished observations).
Time-of-day variations in isolated vascular smooth-muscle contraction and in vivo pressor responses are suppressed in SM-Bmal1–KO mice.
To investigate the role of smooth-muscle BMAL1 in vascular tone,
superior mesenteric arteries were isolated from SM-Bmal1–KO mice
and WT littermates at zeitgeber time 5 (ZT5) and ZT17. Endothelium
was denuded, and their contractile responses to high potassium (K+),
phenylephrine (PE), and serotonin (5-HT) were determined. Consistent with our recent report in abdominal aorta (9), the contractile
responses to all 3 stimuli in mesenteric arteries were higher at ZT5
than at ZT17 in WT littermates (Figure 2, A–E). Strikingly, smoothmuscle–specific Bmal1 deletion abolished the time-of-day variations
in smooth-muscle contractile responses to K+ (Figure 2A), PE (Figure 2, B and C), and 5-HT (Figure 2, D and E). In addition, the maximal contractile responses to all 3 stimuli were markedly suppressed
at both ZT5 and ZT17 in SM-Bmal1–KO mice compared with WT
littermates (Figure 2, A, C, and E).
We next examined the effect of smooth-muscle BMAL1 on vascular structure. We did not find significant differences in the medium
thickness, medium area, lumen area, and ratio of medium to lumen
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in the second branch of mesenteric arteries between SM-Bmal1–KO
mice and WT littermates (Supplemental Figure 1, A and B; supplemental material available online with this article; doi:10.1172/
JCI76881DS1). These data suggest that smooth-muscle Bmal1 deletion has little effect on vascular structure and, thus, that the suppression of contraction amplitude in tissues from SM-Bmal1–KO
mice is unlikely to be attributed to vascular structure changes.
We also determined the contractile responses to K+, PE, and
5-HT in right renal arteries and found suppression in contractile
time-of-day variation and amplitude similar to that found in mesenteric arteries in SM-Bmal1–KO mice (Supplemental Figure 2,
A–E). These data suggest that the effect of smooth-muscle BMAL1
on contractile responses is not limited to mesenteric arteries.
In addition to responding to neuronal and humoral stimulations, vascular smooth muscle in resistance arterioles contracts in
response to mechanical stretch via a mechanism termed myogenic
responses. To determine the role of smooth-muscle BMAL1 in myogenic responses in small resistance arteries that are more relevant to
blood pressure, we investigated the myogenic responses in the fifth
branch of mesenteric arteries (lumen diameters of 55 to 85 μm) isolated from SM-Bmal1–KO mice and WT littermates at ZT5, a time
point when a more pronounced difference in K+-, PE-, and 5-HT–
induced contraction was detected between the 2 mouse strains (Figure 2, A–E). As shown in Figure 3, A and B, in the presence of extracellular Ca2+, when the vascular smooth muscle can generate active
myogenic contraction, the vessel lumen diameter was increased
to a larger extent in response to the pressure steps from 20 to 120
mmHg in SM-Bmal1–KO mice than in WT control mice, indicating
a compromised myogenic response in SM-Bmal1–KO mice. Consistent with this result, when the average spontaneous tone at the
physiological pressure of 60 mmHg was calculated as the percentage decrease in active lumen diameter from the passive diameter
(23), vessels from SM-Bmal1–KO mice exhibited significantly less
spontaneous tone than those in WT littermates (Figure 3B).
When the active myogenic response was eliminated in the
absence of added Ca2+ and the presence of EGTA plus nitroprusside, the difference in vessel lumen increase between 2 strains of
mice was largely diminished (Figure 3A; passive vs. active), indicating that a compromised smooth-muscle myogenic response
rather than a vascular structure change is largely responsible for
the difference between SM-Bmal1–KO mice and WT controls.
Nevertheless, it was noted that a small but significant (P < 0.05)
difference remained in the absence of Ca2+ between the 2 strains
of mice, suggesting that there is a moderate structural change in
the fifth branch of mesenteric arteries from SM-Bmal1–KO mice.
Consistent with this interpretation, there were trends toward a
decrease in the cross-sectional lumen area and an increase in the
cross-sectional wall area and, as a result, a small but significant
increase in wall-to-lumen ratio (Supplemental Figure 3, A–D).
To further verify whether the vascular contractile differences
detected in isolated vascular preparations are present in vivo, we
determined the immediate pressor responses to i.v. injection of
various doses of PE at ZT5 and ZT17. Similar to what we observed
in isolated mesenteric arteries (Figure 2) and renal arteries (Supplemental Figure 2) from WT littermates, the pressor responses
to 10 or 50 μg/kg PE at ZT5 were significantly higher than those
at ZT17, whereas such time-of-day difference was abolished in
jci.org   Volume 125   Number 1   January 2015
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Figure 1. Characterization of SM-Bmal1–KO mice. (A) Analysis of smooth-muscle–specific Cre-mediated chromosome recombination by PCR using genomic
DNA from SM-Bmal1–KO mice. MA, mesenteric artery; AG, adrenal gland; SM, skeletal muscle. (B) Real-time PCR analysis of Bmal1 mRNA expression in
mesenteric arteries (n = 3–5). (C) Representative Western blots of BMAL1 and β-actin protein expression in mesenteric arteries (n = 8). (D–G) Real-time PCR
analysis of Per1 (D and F) and Per2 (E and G) mRNA expression in mesenteric arteries (D and E) and the heart (F and G) (n = 3–5). ***P < 0.001 vs. KO at ZT11.
(H and I) Representative LumiCycle luminescence recordings of PER2-luciferase protein oscillation in MA (H) and SCN-containing brain slice (I).

SM-Bmal1–KO mice (Figure 3C and Supplemental Table 1). In
addition, the pressor responses to 10 or 50 μg/kg PE at ZT5 were
smaller in SM-Bmal1–KO mice compared with those in WT littermates (Figure 3C and Supplemental Table 1).
Taken together, these data demonstrate that smooth-muscle
BMAL1 is essential for the 24-hour variations and normal amplitude of contractile responses in vitro and in vivo.
MLC20 phosphorylation increase is selectively inhibited at ZT5 but
not ZT17 in mesenteric arteries from SM-Bmal1–KO mice. Reversible phosphorylation of the 20-kDa regulatory myosin light chain
(MLC20) is a primary mechanism regulating smooth-muscle
contraction (8); we therefore investigated the possibility that
smooth-muscle BMAL1 may mediate the time-of-day variation of
contraction through regulating MLC20 phosphorylation. Mesenteric arteries were isolated from SM-Bmal1–KO mice and WT littermates at ZT5 or ZT17 and then incubated with PE and 5-HT to
induce MLC20 phosphorylation. We used both PE and 5-HT rather
than a single agonist to stimulate MLC20 phosphorylation to activate various branches of mesenteric arteries, as the contraction
amplitude induced by PE or 5-HT varied at the different branches
of mesenteric arteries (ref. 24 and Figure 2, B–E). Moreover, 2
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agonists were expected to drive the MLC20 phosphorylation to
a higher level, thus providing a relatively larger window for the
detection of a decrease in MLC20 phosphorylation in SM-Bmal1–KO
mice. Two distinct methods, urea glycerol gel electrophoresis
that separates un-, mono-, and diphosphorylated MLC20 (24) and
Western blot using antibodies specific for phosphorylated MLC20
(Thr18/Ser19), were used to determine MLC20 phosphorylation.
In WT littermates, stimulation of the vessels with PE plus
5-HT significantly increased MLC20 phosphorylation at both ZT5
(Figure 4, A–D, lanes 1 vs. 2) and ZT17 (Figure 4, A–D, lanes 5 vs.
6), but the amplitude of MLC20 phosphorylation increase at ZT5
was significantly higher than that at ZT17 (Figure 4, A–D, lanes 2
vs. 6). These results correlate with the larger contractile responses
at ZT5 relative to at ZT17 (Figure 2 and Supplemental Figure 2) and
suggest that the time-of-day variation in contractile amplitude is
mediated, at least in part, by MLC20 phosphorylation.
In SM-Bmal1–KO mice, stimulation of the vessels with PE plus
5-HT also increased MLC20 phosphorylation at both ZT5 (Figure 4,
A–D, lanes 3 vs. 4) and ZT17 (Figure 4, A–D, lanes 7 vs. 8). However,
the amplitude of MLC20 phosphorylation increase in SM-Bmal1–
KO mice was selectively suppressed at ZT5 (Figure 4, A–D, lanes 2
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Figure 2. The time-of-day variation in agonist-induced contractile responses is suppressed in superior mesenteric artery from SM-Bmal1–KO mice. (A)
The plateau response to 143 mM K+ (n = 4–8). (B and C) The concentration-response curve (B) and the maximum response (C) to PE (n = 6–9). **P < 0.01 vs.
WT-ZT17 at 100 μM PE (D and E). The concentration-response curve (D) and the maximum response (E) to 5-HT (n = 6–9). *P < 0.05 vs. WT-ZT17 at 0.1 μM
5-HT; ***P < 0.001 vs WT-ZT17 at 1 or 10 μM 5-HT.

vs. 4), but not at ZT17 (Figure 4, A–D, lanes 6 vs. 8), compared with
that in WT littermates. As a consequence, the difference in the
MLC20 phosphorylation between ZT5 and ZT17 was abolished in
SM-Bmal1–KO mice, which correlates with the abolishment of the
differences in contractile responses between ZT5 and ZT17 in SMBmal1–KO mice (Figure 2 and Supplemental Figure 2).
Identification of ROCK2 as a new target of BMAL1 in mesenteric
arteries. To identify molecular mechanisms that underlie agonistinduced and BMAL1-mediated smooth-muscle contraction, we
investigated several proteins that are either essential components
of contractile apparatus or key regulators of MLC20 phosphorylation. By immunoblot analysis, we compared the expression levels
of the following proteins at ZT5 in mesenteric arteries from SMBmal1–KO and WT littermates: (a) α-SMA; (b) MLC20; (c) myosin
phosphatase target subunit 1 (MYPT1); (d) 17-kDa PKC-potentiated protein phosphatase-1 inhibitor (CPI-17); (e) Rho-kinase
2 (ROCK2); and (f) small–molecular weight G protein RhoA.
Interestingly, among all the proteins investigated, we found that
ROCK2 was selectively decreased in SM-Bmal1–KO mice compared with that in WT littermates (Supplemental Figure 4, A–G).
Since ROCK2 is a key regulator of smooth-muscle contraction and
blood pressure homeostasis and its dysfunction has been implicated in many cardiovascular diseases (25), we therefore tested the
hypothesis that ROCK2 links BMAL1 and time-of-day variations
in vascular smooth-muscle contraction by various approaches.
First, to determine whether BMAL1, as a transcriptional factor,
directly binds Rock2 promoter, we analyzed the mouse Rock2 promoter DNA sequence and identified multiple canonical E-boxes
(CANNTG, where N can be any nucleotide) that BMAL1 can poten-

tially bind to (Figure 5A). To determine whether BMAL1 binds to
these putative E-boxes, we generated a rabbit polyclonal antibody
that specifically recognized BMAL1 (Figure 5B) and performed a
ChIP assay in mesenteric arteries isolated from WT mice at ZT5
and ZT17. As a positive control, we examined whether BMAL1
binds to the Per1 (a classic BMAL1 target) promoter and found that
indeed it did, as expected (Figure 5C). Importantly, we found that
BMAL1 bound to the Rock2 promoter at E-box 5 through E-box 8,
but not at E-box 9 and E-box 10 (Figure 5, A and C). Moreover,
more BMAL1 binding was detected at ZT17 than at ZT5, indicating
that BMAL1 binds to the Rock2 promoter in a time-of-day–dependent manner (Figure 5, C and D).
Second, to investigate whether the binding of BMAL1 to the
Rock2 promoter regulates its activity, we cloned a 3.2-kb mouse
Rock2 promoter, inserted it into a luciferase reporter vector (pGl3Rock2P-Luc), and transfected the pGl3-Rock2P-Luc vector into
aortic vascular smooth-muscle cells (VSMCs) isolated from SMBmal1–KO mice and WT littermates. In WT cells, the Rock2 promoter exhibited a 14-fold increase in luciferase activity over the
pGL3 luciferase vector (Figure 5E, column 1 vs. 2). In contrast,
when transfected into Bmal1-deficient cells, Rock2 promoter activity was abolished (Figure 5E, column 2 vs. 4), suggesting that
BMAL1 is required for Rock2 promoter activity in cultured VSMCs.
Importantly, infection of Bmal1-deficient cells by BMAL1 adenovirus almost completely restored Rock2 promoter activity in a concentration-dependent manner (Figure 5E, column 5 and 6 vs. 4).
Third, we investigated whether smooth-muscle Bmal1 deletion affects Rock2 mRNA expression in vivo. Mesenteric arteries
were isolated from SM-Bmal1–KO and WT littermates at ZT5 and
jci.org   Volume 125   Number 1   January 2015
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MYPT1 phosphorylation between ZT5 and
ZT17 was abolished in SM-Bmal1–KO mice.
Finally, we investigated whether pharmacological inhibition of ROCK2 suppresses
vascular smooth-muscle contraction in a
manner similar to that of genetic-deleting
Bmal1. Endothelium-denuded superior mesenteric arteries were prepared from WT mice
at ZT5 and ZT17 and then stimulated with
5-HT in the presence of Rho kinase inhibitor Y-27632 or vehicle (DMSO). The results
demonstrate that Y-27632 suppressed 5-HT–
induced contractions at both ZT5 and ZT17
(Figure 6D). Importantly, the extent of suppression on the contraction was larger at ZT5
than at ZT17; thus, the difference in 5-HT–
induced contraction between ZT5 and ZT17
was abolished by Rho kinase blockade, which
is similar to that in SM-Bmal1–KO mice (Figure 2 and Supplemental Figure 2).
Impairment of blood pressure circadian
rhythm in SM-Bmal1–KO mice. To investigate
whether smooth-muscle BMAL1 is involved
in blood pressure circadian rhythm, we measured blood pressure of conscious, free-moving SM-Bmal1–KO mice and WT littermates
Figure 3. Myogenic responses in isolated fifth branch of mesenteric arteries and diurnal pressor
using telemetry under 12:12 light/dark (L/D),
2+
responses in vivo are suppressed in SM-Bmal1–KO mice. (A) Passive (in the absence of Ca ) and
constant dark (D/D), and constant light (L/L)
active (in the presence of Ca2+) lumen diameter changes of the fifth branch of mesenteric arteries
over intraluminal pressure from 20 to 120 mmHg. The data were calculated as the percentage of
conditions. Mean arterial pressure (MAP)
the passive lumen diameter at 60 mmHg. *P < 0.05; **P < 0.01 vs. WT-active at 60, 80, 100, and
was significantly decreased under all 3 condi120 mmHg, respectively (n = 6–9). #P < 0.05; ##P < 0.01; ###P < 0.001 vs. WT-passive at 80, 100, and
tions in SM-Bmal1–KO mice compared with
120 mmHg, respectively (n = 6–9). (B) Spontaneous tone was calculated as the percentage decrease
that in WT littermates (Figure 7A).
in active lumen diameter from the passive diameter at 60 mmHg (n = 7–9). (C) Telemetric recording
To investigate whether smooth-muscle
of pressor response to bolus PE injection at ZT5 or ZT17 in anesthetized mice (n = 3).
BMAL1 is involved in the intrinsic blood pressure circadian rhythm, we first determined
ZT17, and Rock2 mRNA was quantified by real-time PCR. In WT
blood pressure in the absence of the dominant external light cue
vessels, Rock2 mRNA was significantly higher at ZT17 than that
under D/D conditions (26). Systolic blood pressure (SBP), diaat ZT5 (Figure 6A). In BMAL1-deficient vessels, Rock2 mRNA
stolic blood pressure (DBP), and pulse pressure were continuousexpression was diminished at both ZT5 and ZT17, but the decrease
ly measured for 7 consecutive days. As shown in Figure 7B, SMwas more dramatic at ZT17 than at ZT5 (Figure 6A). As a result,
Bmal1–KO mice exhibited a decrease in SBP during the subjective
there was no difference in Rock2 mRNA between ZT5 and ZT17 in
dark phase without an apparent change during the subjective
Bmal1-deficient mesenteric arteries.
light phase. An analysis of the data using a nonlinear least-square
Fourth, we investigated whether BMAL1 regulates the timefitting program, PHARMFIT (27), illustrated that the SBP circaof-day variations in ROCK2 activity. We determined the phosdian oscillation amplitude was significantly decreased (Figure
phorylation level of MYPT1 at Thr853 (an index of ROCK2 acti7C) and the acrophase (time of the peak) was significantly shifted
vation) in mesenteric arteries isolated from SM-Bmal1–KO mice
forward (Figure 7D), but the period length (the time elapsed for 1
and WT littermates at ZT5 and ZT17. In WT vessels, PE plus 5-HT
complete oscillation) was unaltered (Figure 7E) in SM-Bmal1–KO
significantly increased MYPT1 phosphorylation at ZT5 (Figure 6,
mice relative to WT littermates.
B and C, lane 1 vs. 2) and ZT17 (Figure 6, B and C, lane 5 vs. 6). The
A similar but more dramatic effect of smooth-muscle BMAL1
amplitude of agonist-induced MYPT1 phosphorylation at ZT5 was
on blood pressure circadian rhythm was also observed in DBP
significantly higher than that at ZT17 (Figure 6, B and C, lane 2 vs.
(Figure 7F). The pressure levels during both the subjective dark
6), which is consistent with larger contractile responses (Figure 2
and light phases were decreased in the SM-Bmal1–KO mice, but
and Supplemental Figure 2) and MLC20 phosphorylation (Figure
the amplitude of decrease was bigger during the subjective dark
phase than during the subjective light phase. Consequently, the
4) at ZT5 than at ZT17 in WT mice. In contrast, in SM-Bmal1–KO
amplitude of DBP oscillation was substantially decreased. The
mice, agonist-induced MYPT1 phosphorylation was selectively
acrophase of DBP also shifted forward. Similar to SBP, the period
reduced at ZT5 (Figure 6, B and C, lane 2 vs. 4), but not ZT17 (Figlength of the DBP was not different between the 2 strains of mouse.
ure 6, B and C, lane 6 vs. 8). Consequently, the difference in the
328

jci.org   Volume 125   Number 1   January 2015

Downloaded from http://www.jci.org on November 16, 2015. http://dx.doi.org/10.1172/JCI76881

The Journal of Clinical Investigation  

Research article

Figure 4. The time-of-day variations in agonist-induced MLC20 phosphorylation are diminished in mesenteric arteries from SM-Bmal1–KO mice. (A and
C) Representative urea/glycerol gel (A) and quantitative data (C; n = 7) of MLC20 phosphorylation induced by PE (100 μM) plus 5-HT (10 μM) for 2 minutes.
Un-P MLC20, unphosphorylated MLC20; Mono-P MLC20, monophosphorylated MLC20; Di-P MLC20, diphosphorylated MLC20; MLC20-T, total MLC20, including
un-, mono-, and diphosphorylated MLC20. (B and D) Representative Western blots (B) and quantitative data (D; n = 8) of MLC20 phosphorylation induced by
PE plus 5-HT using the antibodies specific for phosphorylated MLC20 (Thr18 and Ser19) and total MLC20 protein.

The most striking effect of smooth-muscle BMAL1 on blood
pressure circadian rhythm was seen in pulse pressure (Figure 7G).
The level was significantly higher in the SM-Bmal1–KO mice than
in the WT littermates due to a larger decrease in DBP than in SBP.
In addition, JTK-cycle analysis (28) of the pulse pressure illustrated that the circadian oscillation of pulse pressure observed in WT
littermates was abolished in SM-Bmal1–KO mice.
Neither the level nor the circadian oscillations of the locomotor activity, however, were altered in the SM-Bmal1–KO mice compared with WT littermates (Figure 7H). This result is consistent
with the data showing that the Bmal1 gene remains intact in brain
(Figure 1A) and that its target protein PER2 oscillation is normal
(Figure 1I), indicating that the suppressed amplitude and shifted
acrophase of blood pressure circadian oscillation in SM-Bmal1–KO
mice are not due to changes in the SCN central pacemaker.
We also examined the effect of smooth-muscle BMAL1 on
the heart rate (HR). Interestingly, smooth-muscle Bmal1 deletion
decreased the HR during both the subjective dark and light phases (Figure 7I), but had no effect on the HR circadian oscillation
amplitude (Figure 7J), acrophase (Figure 7K), and period length
(Figure 7L). These results are consistent with the data showing
that Per1 and Per2 mRNA oscillation remains normal in the heart
(Figure 1, F and G), indicating that the suppressed amplitude and
shifted acrophase of blood pressure circadian oscillation in SMBmal1–KO mice are unlikely to be attributed to changes in the HR.

To investigate whether the effect of smooth-muscle Bmal1
deletion on blood pressure circadian rhythm is exacerbated by
light, we then determined blood pressure for 7 consecutive days
in the presence of L/L when the SCN central pacemaker was disrupted (26). We found Bmal1 deletion in smooth muscle caused
changes in BP (Supplemental Figure 5) very similar to those that
occurred under D/D conditions, including a decrease in SBP, DBP,
MAP, and HR (Supplemental Figure 5, A, E, F, and I), a decrease
in the amplitude of SBP oscillation (Figure 7B) and no change in
the acrophase and the period length of SBP oscillations (Figure 7,
C and D), an increase in pulse pressure (Supplemental Figure 5G),
and no effect on locomotor activity and HR circadian rhythm (Supplemental Figure 5, H–L).
Interestingly, there were 2 changes in blood pressure circadian rhythm observed in both SM-Bmal1–KO mice and WT littermates under L/L conditions when compared with those under
D/D conditions. First, under L/L conditions, only 1 single peak
was observed in SBP, DBP, locomotor activity, and HR during
the subjective dark phase (Supplemental Figure 5, A, E, F, H, and
I), whereas under D/D conditions, 2 peaks were observed during the subjective dark phase: one at the beginning and another
at the end of the subjective dark phase (Figure 7, B, F, H, and I).
Second, the period length of SBP oscillation was longer: 25.0 ±
0.1 (L/L) vs. 24.0 ± 0.03 (D/D) hours (n = 12 each, P < 0.0001).
The peak of the SBP, DBP, and MAP as well as locomotor activity
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A moderate Bmal1 deletion was seen in the heart
in SM-Bmal1–KO mice (Z.
Guo and M. Gong, unpublished observations), which
is consistent with a moderate decrease in the HR in
SM-Bmal1–KO mice (Figure
7I, Supplemental Figure
5I, and Supplemental Figure 6I). To ensure that the
observed blood pressure
alterations in SM-Bmal1–
KO mice resulted from
smooth-muscle Bmal1 deletion but not cardiomyocyte
Bmal1 deletion, we measured blood pressure in an
inducible cardiomyocytespecific
Bmal1-knockout
mouse model (iCS-Bmal1–
KO), which was generated
by crossing Bmal1flox/flox mice
(18) with cardiac-specific
MerCreMer
recombinase
mice (29), as we previously
reported (30). As shown in
Supplemental Figure 7B,
Figure 5. BMAL1 binds to Rock2 promoter in mesenteric arteries and is required for Rock2 promoter activity in
under
12:12 L/D conditions,
cultured VSMCs. (A) Schematic diagram of a 3.5-kb mouse Rock2 promoter showing the positions of putative E-boxes
neither the MAP level nor
(E) 1 to 10 and ChIP PCR primers relative to the translational start site (TSS). ChIP-F, forward primers; ChIP-R, reverse
primers. (B) Characterization of the BMAL1 antibody by Western blots using cell lysate from Bmal1-deficient (KO) and
the circadian oscillations of
WT mouse aortic VSMCs (mVSMC) as well as human embryonic kidney 293 cells (HEK293), transfected with a pSport6
the MAP were altered in the
control vector (Ctrl) or a pSport6 vector expressing human BMAL1 (hBMAL1). (C and D) Representative ChIP-PCR (C)
iCS-Bmal1–KO mice comand quantitative data (D; n = 4) show that BMAL1 binds to the Per1 promoter and the Rock2 promoter at E-boxes 5 to
pared with those in iCS8, but not E-boxes 9 to 10, in a time-of-day–dependent manner. (E) Restoration of Rock2 promoter activity by BMAL1
Bmal1–WT mice.
adenovirus–mediated gene expression in Bmal1-deficient mVSMCs (+, low dose; ++, high dose; n = 3–6).
To test the possibility that the loss of smoothmuscle tone in SM-Bmal1–KO mice may have an effect on the
and HR during the subjective dark phase shifted gradually from
baroreflex function, thus contributing to the loss of blood pressure
in the middle of the subjective dark phase to the end of the subcircadian rhythm, we determined the spontaneous baroreflex senjective dark phase over the 7-day period (Supplemental Figure 5,
sitivity across the 24-hour day under 12:12 L/D conditions in conA, E, F, H, and I).
scious and free-moving SM-Bmal1–KO mice and WT littermates
We also determined the blood pressure oscillation under 12:12
using the sequence method (31). Consistent with the previous
L/D conditions to investigate whether the external light cue was
reports in humans (31, 32), the spontaneous baroreflex sensitivity
able to correct the compromised blood pressure circadian oscillain WT littermates exhibited time-of-day variations with a higher
tion in the SM-Bmal1–KO mice. As shown in Supplemental Figure
sensitivity during the resting phase (the light phase in mice) than
6, A–L, changes observed in SBP, DBP, pulse pressure, locomotor
during the active phase (the dark phase in mice; Supplemental
activity, and HR were very similar under D/D and L/L conditions,
Figure 8). In contrast, the spontaneous baroreflex sensitivity in
indicating that light, a principal entraining signal to the SCN,
SM-Bmal1–KO mice was diminished across a 24-hour period, with
has little effect on impaired blood pressure circadian rhythm by
a more pronounced decrease during the light phase. Importantly,
smooth-muscle Bmal1 deletion.
the difference in spontaneous baroreflex sensitivity between light
To ensure that the observed blood pressure alterations in SMand dark phases was abolished in the SM-Bmal1–KO mice.
Bmal1–KO mice resulted from smooth-muscle Bmal1 deletion, but
In summary, selective deletion of Bmal1 from smooth muscle
not Cre recombinase expression, we measured blood pressure in
but not from cardiomyocyte decreased the 24-hour MAP. In parthe SM22α-Cre mice under 12:12 L/D conditions. No differences in
ticular, deletion of Bmal1 from smooth muscle compromised blood
either blood pressure level or circadian oscillations were observed
pressure circadian rhythm without affecting locomotor activity. In
between the age- and sex-matched SM22α-Cre mice and Bmal1flox/flox
addition, deletion of Bmal1 from smooth muscle altered 2 of the 3
mice (Supplemental Figure 7A).
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Figure 6. The time-of-day
variation of Rock2 mRNA
expression and ROCK2
kinase activity is regulated
by BMAL1 and is involved in
the time-of-day variation of
smooth-muscle contraction.
(A) Real-time PCR analysis of
Rock2 mRNA expression in
mesenteric arteries (n = 3–5). (B
and C) Representative Western
blots (B) and quantitative data
(C; n = 7–8) of total MYPT1
(T-MYPT1) and phosphorylated
MYPT1 at Thr853 (p-MYPT1853)
in mesenteric arteries. (D)
Concentration-response curve
showing that the time-of-day
variation in vasoconstriction
induced by 5-HT was diminished by pretreatment of mesenteric arteries with Rho-kinase
inhibitor Y27632 (10 μM, 30 min;
n = 7–8). Veh, vehicle (DMSO).
*P < 0.05 vs. ZT17 + vehicle at
10 μM 5-HT.

major characteristics of the blood pressure oscillation: it decreased
the oscillation amplitude and forward shifted the acrophase without affecting the period length. Moreover, deletion of Bmal1 from
smooth muscle markedly elevated pulse pressure level, abolished
pulse pressure circadian rhythm, and diminished the difference
between the light and dark phases in baroreflex sensitivity.
Lack of Bmal1 in smooth muscle does not affect light condition–
induced change in blood pressure circadian oscillation. As shown in
Figure 8A, in the WT littermates, the blood pressure oscillation
amplitude gradually decreased from L/D to D/D and to L/L conditions. In contrast, the acrophase (Figure 8B) and period length
(Figure 8C) of the blood pressure circadian oscillation remained
constant under L/D and D/D conditions, but significantly
increased under L/L conditions. Interestingly, deletion of Bmal1
from smooth muscle significantly suppressed the blood pressure
circadian oscillation amplitude and forward shifted the acrophase
(Figure 7 and Supplemental Figures 5 and 6), but it had no detectable effect on L/L-induced changes in blood pressure circadian
oscillations, including suppression in oscillation amplitude (Figure 8A), delay in acrophase (Figure 8B), and increase in oscillation period length (Figure 8C) as well as L/L-induced changes in
locomotor activity (Figure 8D). This indicates a minimal role of
vascular smooth-muscle BMAL1 and contractility in light condition–induced alterations in blood pressure circadian oscillation.

Discussion

Major findings of the current study are as follows: (a) smooth-muscle–specific deletion of Bmal1 did not affect the central pacemaker
SCN, but drastically suppressed the amplitude and the time-of-day
variations in vasoconstriction in isolated preparations in response
to various agonist stimulations, in myogenic response to pressure

increase, and in in vivo pressor responses in anesthetized mice;
(b) the inhibition of agonist-induced vasoconstriction was associated with suppression of MLC20 phosphorylation, Rock2 mRNA,
and activity; moreover, BMAL1 directly bound to Rock2 promoter
in a time-of-day–dependent manner in mesenteric arteries and
was required for Rock2 promoter activity in cultured VSMCs; (c) in
mice lacking smooth-muscle Bmal1, the blood pressure level was
decreased; blood pressure circadian oscillation amplitude was
decreased, whereas light-induced blood pressure changes were
not affected; acrophase was forward shifted, but the period length
and light-induced changes remained unaltered; and (d) smoothmuscle–specific deletion of Bmal1 markedly elevated pulse pressure level and abolished pulse pressure circadian rhythm.
How do our findings contribute to the current understanding
of blood pressure circadian rhythm? It was long believed that all
circadian rhythms, including blood pressure circadian rhythm,
were primarily generated and controlled by the central pacemaker
SCN. Indeed, ablation of the SCN results in the loss of circadian
oscillation of blood pressure, along with the loss of endocrine and
behavioral rhythms (33). However, recent studies illustrate that
the behavioral circadian rhythm that is mainly controlled by the
SCN does not correlate precisely with the blood pressure circadian rhythm in a 24-hour period (6, 34), indicating an involvement
of additional mechanisms in the generation and maintenance of
blood pressure circadian rhythm. This concept is supported by the
discovery that each of the core clock genes present in the SCN are
also expressed and function in peripheral tissues (4–7). However,
which clock gene in which peripheral tissue or tissues contributes
to the blood pressure circadian rhythm remains elusive.
The results of the current study demonstrated that smoothmuscle BMAL1 substantially contributes to the maintenance of
jci.org   Volume 125   Number 1   January 2015

331

Downloaded from http://www.jci.org on November 16, 2015. http://dx.doi.org/10.1172/JCI76881

Research article

The Journal of Clinical Investigation  

Figure 7. Circadian rhythms in blood pressure, but not in locomotor activity and HR, are altered in SM-Bmal1–KO mice under D/D conditions. (A)
24-hour MAP under 12:12 L/D, D/D, and L/L conditions (n = 5–8). (B and F–I) 7-day SBP (B), DBP (F), pulse pressure (G), locomotor activity (H), and HR (I)
under D/D conditions (n = 5–7). (C–E) SBP circadian oscillations in amplitude (C), acrophase (D), and period length (E). (J–L) HR circadian oscillations in
amplitude (J), acrophase (K), and period length (L).

normal blood pressure levels as well as blood pressure circadian
rhythm. The MAP decreased by about 9 to 10 mmHg in the global
BMAL1-knockout mice (16). In mice lacking smooth-muscle Bmal1,
an approximately 7 mmHg blood pressure decrease was observed
(Figure 7A), whereas in mice lacking cardiomyocyte Bmal1, no
difference in blood pressure levels was observed (Supplemental
Figure 7B), suggesting a major contribution of the smooth-muscle
BMAL1 to the overall blood pressure level decrease in the global
Bmal1-knockout mice. Moreover, blood pressure circadian rhythm
amplitude and acrophase were significantly altered in mice lacking smooth-muscle Bmal1 under D/D (Figure 7, B–G), L/L (Supplemental Figure 5), and 12:12 L/D conditions (Supplemental Figure
6). A more striking effect of deleting smooth-muscle Bmal1 on
blood pressure was observed in pulse pressure, with a dramatic
increase in pulse pressure level and a complete loss of pulse pressure circadian rhythm (Figure 7G and Supplemental Figure 5G).
While the significance of pulse pressure circadian rhythm remains
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elusive, multiple population-based cohort studies (35–37) and randomized trials of hypertension treatment (38) have shown that
increased pulse pressure is associated with a variety of adverse
cardiovascular outcomes, and there are reports that ambulatory
monitoring of pulse pressure substantially refines the risk stratification in hypertensive patients (39, 40). Thus, our finding that
smooth-muscle BMAL1 regulates the level and circadian rhythms
of blood pressure including pulse pressure may have an important
implication for human health.
How does smooth-muscle BMAL1 regulate blood pressure
circadian rhythm? We and others have reported that vascular
smooth-muscle contractile responses to various agonists exhibit
a time-of-day variation (9–14). Therefore, one potential mechanism is that smooth-muscle BMAL1 regulates the time-of-day
variation of vasoconstriction and thereby participates in the regulation of blood pressure circadian rhythm. Several lines of evidence from the current study support this potential mechanism.
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Figure 8. The change in blood pressure circadian rhythm with light is not altered in SM-Bmal1 mice. (A–C) The amplitude (A), acrophase (B), and period
length (C) of the rhythmicity were calculated from SBP data collected under 12:12 L/D, D/D, and L/L conditions (n = 8). (D) 12-hour means of locomotor
activity under L/D, D/D, and L/L conditions (n = 8). “L”, subjective light condition. “D”, subjective dark condition.

First, the time-of-day variation in contractile responses to high
K+ depolarization and agonist (PE and 5-HT) stimulation was
abolished in smooth-muscle Bmal1-deficient and endotheliumdenuded superior mesenteric arteries (Figure 2) and renal arteries (Supplemental Figure 2). We denuded endothelium, as we
have usually done in our experiments (9, 41–44), to focus on
studying smooth-muscle function, as a recent report demonstrated that selective deletion of a gene from smooth muscle affected
endothelium function (45). Second, the myogenic responses were
attenuated in the fifth branch of mesenteric arteries from SMBmal1–KO mice compared with that from WT littermates (Figure
3, A and B). Surprisingly, a moderate inward eutrophic vascular
remodeling was found in the fifth branch of mesenteric arteries
(Supplemental Figure 3), but not in the second branch of mesenteric arteries (Supplemental Figure 1). Such selective and moderate vascular remodeling may be a direct effect of smooth-muscle
Bmal1 deletion or a compensatory response to a decrease in blood
pressure. Further studies are required to clarify this issue. Third,
in line with these ex vivo vasoconstriction studies, the time-ofday variation in pressor response to PE was also diminished in
anesthetized SM-Bmal1–KO mice (Figure 3C). Fourth, the timeof-day variation in MLC20 phosphorylation induced by agonist
was attenuated in smooth-muscle Bmal1-deficient mesenteric
arteries (Figure 4). However, one surprising finding of the current study is that the phase of vasoconstriction does not correlate
with the phase of blood pressure level in WT littermates (Figure
2 vs. Figure 7, B, F, and G). This finding is unlikely to be attributable to the time delay caused by the ex vivo tissue preparation

and tension measurement because we (Figure 3C) and others
(46) have demonstrated a similar “antiphase” temporal relationship between the in vivo PE-induced pressor response and blood
pressure. This paradoxical observation suggests the relationship
between the time-of-day vasoconstriction variation and blood
pressure circadian rhythm is complex rather than linear. This is
not entirely unexpected, since vasoconstriction-induced blood
pressure change will trigger sympathetic, endocrine, and local
environmental changes via multiple mechanisms. Indeed, we
(Supplemental Figure 8) and others (31, 32) have demonstrated
that the spontaneous baroreflex sensitivity showed time-of-day
variations, which is in phase with the time-of-day vasoconstriction variation (Supplemental Figure 8 vs. Figure 2).
The molecular mechanism underlying the time-of-day variation in vascular smooth-muscle contraction remained completely
unknown until Saito et al. recently reported that, in cultured cells
and isolated aorta, the expression and activity of ROCK2 exhibited a circadian rhythm in phase with that of MLC20 phosphorylation (47). The current study demonstrates for the first time, to our
knowledge, that, in isolated mesenteric arteries, BMAL1 directly
binds to the E-box–containing region in the Rock2 promoter in a
time-of-day–dependent manner (Figure 5, C and D), which is in
phase with Rock2 mRNA expression (Figure 6A). A pivotal role of
smooth-muscle BMAL1 in Rock2 transcriptional regulation was
further demonstrated by complete loss of Rock2 promoter activity in Bmal1-deficient VSMCs and by the complete restoration of
Rock2 promoter activity by restoring BMAL1 expression using adenovirus-mediated gene transfer (Figure 5E). Moreover, a temporal
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correlation of ROCK2 function (pMYPT1853 phosphorylation) with
vasoconstriction (Figure 6, B and C, vs. Figure 2) and MLC20 phosphorylation (Figure 6, B and C, vs. Figure 4) was observed in WT
mice, but lost in SM-Bmal1–KO mice.
In summary, the current study provides several lines of evidence indicating that smooth-muscle BMAL1 is critical for timeof-day–dependent vasoconstriction and thereby blood pressure
circadian rhythm. Moreover, the current study also reveals a
mechanism by which smooth-muscle BMAL1 regulates MLC20
phosphorylation and vasoconstriction via ROCK2 in a time-ofday–dependent manner. Since disruption of blood pressure circadian rhythm is implicated in many human diseases, including hypertension, acute myocardial infarction, sudden cardiac
death, and stroke and is emerging as an index for future target
organ damage and cardiovascular outcomes (2, 3), the new
mechanistic insights into the daily control of vasoconstriction
and blood pressure obtained in the current study could contribute to the foundation for future elucidation of the pathogenesis
of many cardiovascular diseases involving disruption of blood
pressure circadian rhythm.

Methods

Animals. SM-Bmal1–KO mice and iCS-Bmal1–KO mice were generated by crossing Bmal1flox/flox mice (18) with smooth-muscle–specific SM22α-Cre knockin mice (19) and cardiac-specific MerCreMer
recombinase mice (30), respectively. SM-Bmal1–KO/Per2Luc mice
were generated by crossing SM-Bmal1–KO mice with mPer2Luc knockin mice (48). Bmal1flox/flox mice, SM22α-Cre knockin mice, cardiac-specific MerCreMer recombinase mice, and mPer2Luc knockin mice were
purchased from the Jackson Laboratory. Only male mice at 12 to 16
weeks of age were used, and the mice were kept on a 12:12 L/D cycle
unless indicated otherwise.
Analysis of smooth-muscle–specific Cre-mediated chromosome
recombination in SM-Bmal1–KO mice. Genomic DNAs were extracted
from various tissues of SM-Bmal1–KO mice and subjected to PCR
analysis using a combination of 3 primers that were able to simultaneously detect both Bmal1-KO and WT (Bmal1flox/flox) gene products
as described (18).
Quantitative analysis of mRNA expression. Mesenteric arteries were
isolated from SM-Bmal1–KO mice and WT littermates at ZT5, ZT11,
ZT17, and ZT23 (ZT0, light on; ZT12, light off). RNA extraction, cDNA
synthesis, and real-time PCR were carried out as described (41, 49).
The real-time PCR primers for mouse Per1 and Per2 were the same as
those previously described (9). The real-time PCR primers for mouse
Rock2 are described in Supplemental Table 2.
Real-time luminescence analysis of Per2 gene expression. Mesenteric
arteries and coronal brain sections containing SCN were isolated from
SM-Bmal1–KO/Per2Luc mice and Per2Luc knockin mice at ZT10 to ZT11
and were then cultured in 35-mm Petri dishes at 36°C in a light-tight,
water-jacketed incubator. Luminescence was continuously recorded
by LumiCycle (Actimetrics) as described (48).
Isometric tension measurement. Mesenteric arteries and right renal
arteries were isolated from SM-Bmal1–KO mice and WT littermates at
ZT5 or ZT17. Superior mesenteric arteries and renal arteries were cut
into small spiral strips (about 3 mm in length and 350 μm in width).
Endothelium was denuded, and isometric contractions were measured as described (9, 41–44, 50).
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Assessment of mesenteric myogenic tone. The fifth branches of mesenteric arteries with an inner diameter of 55 to 85 μm were prepared
from SM-Bmal1–KO mice and WT littermates and then cannulated in
a pressure myograph system (Living Systems Instrumentation). An
active and passive pressure-diameter curve was recorded in the presence of Ca2+ and the absence of Ca2+ plus EGTA and nitroprusside,
respectively, by 20 mmHg stepwise increase of intraluminal pressure
from 0 to 120 mmHg in a physiological buffer at 37°C gassed with a
95% O2–5% CO2 gas mixture as described (24).
Analysis of MLC20 phosphorylation. Mesenteric arteries were isolated from SM-Bmal1–KO mice and WT littermates at ZT5 or ZT17.
After equilibration in normal Krebs-Ringer bicarbonate buffer at 37°C
for 30 minutes, mesenteric arteries were stimulated with 5-HT (10
μM) plus PE (100 μM) for 2 minutes, followed by immediate freezing in liquid nitrogen–chilled acetone containing 10% trichloroacetic
acid. MLC20 phosphorylation was then determined by urea/glycerolPAGE as described (24) and by immunoblots using a MLC20 phosphorylation-specific antibody (Thr18/Ser19; Cell Signaling Technology) as
described (49, 51–53).
BMAL1 ChIP assay. A custom ChIP-grade BMAL1 rabbit polyclonal
antibody was produced by Genemed Synthesis against mouse BMAL1
amino acids 59–66 (TDKDDPHGRLEYAEHQGR). BMAL1 antibody
was purified from antisera by immunoaffinity chromatography using
the antigen peptide coupled to agarose beads as described (49).
Mesenteric arteries were isolated from Bmal1flox/flox mice at ZT5
and ZT17. Mesenteric arteries were fixed with 1% formaldehyde for 15
minutes to preserve the protein-DNA interactions. Mesenteric arteries
were lysed in an SDS buffer containing protease inhibitors, and chromatin was fragmented by sonication. Three mesenteric arteries were
pooled as 1 sample for BMAL1 ChIP analysis. The diluted chromatin
was precleared by incubating with salmon sperm DNA (Life Technologies) and protein A/G agarose beads (Santa Cruz Biotechnology Inc.)
and subjected to immunoprecipitation by incubating with the BMAL1
antibody (2 μg) or an equal amount of nonspecific rabbit IgG (Vector
Laboratory). The immune complexes were pulled down by protein
A/G agarose beads and eluted. The crosslinks between protein and
DNA were reversed by heating at 65°C for 4 hours. The released DNA
was purified and amplified by PCR. The primers for mouse Per1, mouse
Rock2 E-boxes 5 to 8, and mouse Rock2 E-boxes 9 to 10 are described
in Supplemental Table 2.
Cloning mouse Rock2 promoter. A mouse bacterial artificial chromosome clone containing the mouse Rock2 promoter was purchased
from Life Technologies. An approximately 3.2-kb PCR product
(–2,402 to +807 bp, relative to the translational initiation site) was
amplified by PCR using primers as described in Supplemental Table
2, verified by DNA sequencing (Z. Guo and M. Gong, unpublished
observations), and subcloned into the pGL3 basic vector (Promega)
at the XhoI and KpnI sites.
ROCK2 promoter assay. Bmal1-deficient and WT VSMCs were isolated from SM-Bmal1–KO and WT littermate aortas as described (49,
54, 55). Cells were cotransfected with pGl3-Rock2 luciferase vector and
a Renilla luciferase using Lipofectamine-Plus Reagent (Life Technologies). A human BMAL1 adenovirus was purchased from Vector BioLabs
and was purified by CsCl density gradient centrifugation as described
(42). BMAL1 adenoviral expression in VSMC was verified by Western
blot (Z. Guo and M. Gong, data not shown). Rock2 promoter activity was
assayed by a modified dual luciferase enzyme assay as described (55).
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Telemetric measurement of blood pressure circadian rhythm and
diurnal pressor responses. SM-Bmal1–KO mice and WT littermates were
chronically instrumented in the left common carotid artery with a
telemetry probe as described (27). After 10 days of recovery, SBP, DBP,
MAP, pulse pressure, HR, and locomotor activity data were collected
for 3 consecutive days on a 12:12 L/D cycle, 7 consecutive days under
D/D conditions, and 7 consecutive days under L/L conditions, respectively. Diurnal pressor responses to PE were measured in anesthetized
mice either at ZT5 or ZT17 as described (9).
Statistics. All data were expressed as mean ± SEM. For comparison of 1 parameter between 2 strains of mice, statistical analysis was
performed using 2-tailed, unpaired Student’s t test. For comparison
of multiple parameters between 2 strains of mice at a single time
point, statistical analysis was performed using 1-way ANOVA with
a Newman-Keuls post test. For comparison of multiple parameters
between 2 strains of mice across various ZT time points, various
concentrations, or various pressures, statistical analysis was performed using 2-way ANOVA with repeated measures and Bonferroni’s post test. P < 0.05 was considered significant. P ≥ 0.05 was
considered NS.
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